SEC 13F Intelligence

Managers / Q2 2021 · view latest →

Healthcare Value Capital, LLC

CIK 0001458461 · 50 TICE BLVD, SUITE 140, WOODCLIFF LAKE, NJ, 07677 · 212-488-5411

Reported Value
$50M
Q2 2021
Positions
23
Filings on Record
11
2019–present window
Filed
Aug 16, 2021
original filing

Summary

Healthcare Value Capital, LLC reported $50M in U.S.-listed holdings across 23 positions for Q2 2021.

Its largest position, GILD, represents 10.3% of the portfolio.

Compared with Q1 2021, the fund opened 3 new positions and exited 2.

Portfolio Metrics

Turnover
+14.5%
vs prior filed quarter
Top-10 Concentration
+67.9%
share of reported value
Largest Position
+10.3%
Gilead Sciences
New / Exited
3 / 2
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $26MQ1 ’19Q2 ’19: $53MQ3 ’19: $55MQ3 ’19Q4 ’19: $34MQ1 ’20: $59MQ1 ’20Q2 ’20: $39MQ3 ’20: $30MQ3 ’20Q4 ’20: $30MQ1 ’21: $45MQ1 ’21Q2 ’21: $50MQ3 ’21: $51MQ3 ’21filingsflow.com

Portfolio Composition

By security type
Common Stock: 70.6%Other: 23.4%ADR: 6.0%
  • Common Stock · 70.6% · $35M
  • Other · 23.4% · $12M
  • ADR · 6.0% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MDXGMIMEDX GROUP INCNEW+125.0K125.0K+$2M$2M
PROSHARES TRNEW+100.0K100.0K+$914,000$914,000
PROSHARES TR IINEW+25.0K25.0K+$602,000$602,000
BMYBRISTOL-MYERS SQUIBB COADDED+25.0K50.0K+$2M$3M
AZNNASTRAZENECA PLCADDED+25.0K50.0K+$2M$3M
MRKMERCK & CO INCADDED+20.0K40.0K+$2M$3M
AUPHAURINIA PHARMACEUTICALS INCSOLD OUT−100.0K0−$1M$0
PROSHARES TR IISOLD OUT−100.0K0−$935,000$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

18 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1GILDGILEAD SCIENCES INChistory →COM10.29%$5M75.0K
2GLAXOSMITHKLINE PLCSPONSORED ADR7.93%$4M100.0K
3PFEPFIZER INChistory →COM7.80%$4M100.0K
4ALKSALKERMES PLChistory →SHS7.33%$4M150.0K
5BMYBRISTOL-MYERS SQUIBB COhistory →COM6.66%$3M50.0K
6MRKMERCK & CO INChistory →COM6.20%$3M40.0K
7AZNNASTRAZENECA PLChistory →SPONSORED ADR5.97%$3M50.0K
8CLOVIS ONCOLOGY INCCOM5.78%$3M500.0K
9IRWDIRONWOOD PHARMACEUTICALS INChistory →COM CL A5.13%$3M200.0K
10AMRYT PHARMA PLCSPONSORED ADS4.83%$2M200.0K
11COLLCOLLEGIUM PHARMACEUTICAL INChistory →COM4.71%$2M100.0K
12ANTARES PHARMA INCCOM4.34%$2M500.0K
13TYME TECHNOLOGIES INCCOM3.77%$2M1.50M
14VYNE THERAPEUTICS INCCOM3.15%$2M450.0K
15GREENLANE HLDGS INCCL A3.12%$2M350.0K
16MDXGMIMEDX GROUP INChistory →COM3.12%$2M125.0K
17ADAMAS PHARMACEUTICALS INCCOM1.05%$528,000100.0K
18GAMIDA CELL LTDSHS0.96%$481,00075.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$51M25Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$50M23Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$45M22May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$30M17Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$30M18Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$39M19Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$59M26May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$34M16Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$55M22Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$53M19Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$26M10May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.